JP2021534202A5 - - Google Patents
Info
- Publication number
- JP2021534202A5 JP2021534202A5 JP2021509910A JP2021509910A JP2021534202A5 JP 2021534202 A5 JP2021534202 A5 JP 2021534202A5 JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021534202 A5 JP2021534202 A5 JP 2021534202A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- alkyl
- note
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719938P | 2018-08-20 | 2018-08-20 | |
| US62/719,938 | 2018-08-20 | ||
| PCT/US2019/047309 WO2020041344A1 (en) | 2018-08-20 | 2019-08-20 | Methods and compositions for drugs to treat ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534202A JP2021534202A (ja) | 2021-12-09 |
| JP2021534202A5 true JP2021534202A5 (enExample) | 2022-08-26 |
Family
ID=69591159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509910A Pending JP2021534202A (ja) | 2018-08-20 | 2019-08-20 | 眼科疾患を処置する為の薬物の為の方法及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12221447B2 (enExample) |
| EP (1) | EP3840745A4 (enExample) |
| JP (1) | JP2021534202A (enExample) |
| KR (1) | KR20210049857A (enExample) |
| CN (1) | CN112654353A (enExample) |
| AU (1) | AU2019326448A1 (enExample) |
| BR (1) | BR112021003189A2 (enExample) |
| CA (1) | CA3109809A1 (enExample) |
| CO (1) | CO2021003607A2 (enExample) |
| IL (1) | IL280952A (enExample) |
| MX (1) | MX2021002028A (enExample) |
| SG (1) | SG11202101522WA (enExample) |
| TW (1) | TW202021968A (enExample) |
| WO (1) | WO2020041344A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109809A1 (en) | 2018-08-20 | 2020-02-27 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
| JP7706671B2 (ja) * | 2023-06-16 | 2025-07-11 | 千寿製薬株式会社 | 眼疾患モデル動物 |
| JP7776899B1 (ja) * | 2024-06-14 | 2025-11-27 | 株式会社坪田ラボ | 局所投与用の重症眼表面疾患の処置剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4153693B2 (ja) * | 2001-04-25 | 2008-09-24 | 大日本住友製薬株式会社 | 新規なＣａＭＫＫ阻害剤 |
| GB0600763D0 (en) * | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof |
| GB0600764D0 (en) * | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | Organic compound, optical crystal film and method of production thereof |
| WO2008045273A2 (en) | 2006-10-12 | 2008-04-17 | Duke University | Camkk(beta) as a target for treating obesity |
| JP5464395B2 (ja) | 2008-02-01 | 2014-04-09 | 大陽日酸株式会社 | 重水素化された芳香環又は複素環を有する化合物の製造方法 |
| US8354557B2 (en) | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US8704001B2 (en) | 2008-09-16 | 2014-04-22 | Concert Pharmaceuticals, Inc. | Deuterated 2-amino-3-hydroxypropanoic acid derivatives |
| US20130253035A1 (en) | 2010-08-16 | 2013-09-26 | Duke University | Camkk-beta as a target for treating cancer |
| US8895118B2 (en) * | 2010-11-09 | 2014-11-25 | Crysoptix K.K. | Negative dispersion retardation plate and achromatic circular polarizer |
| SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2895846A1 (en) | 2012-12-20 | 2014-06-26 | Concert Pharmaceuticals, Inc. | Deuterated alk inhibitors |
| US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| CA3109809A1 (en) | 2018-08-20 | 2020-02-27 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
-
2019
- 2019-08-20 CA CA3109809A patent/CA3109809A1/en active Pending
- 2019-08-20 KR KR1020217008504A patent/KR20210049857A/ko not_active Ceased
- 2019-08-20 MX MX2021002028A patent/MX2021002028A/es unknown
- 2019-08-20 AU AU2019326448A patent/AU2019326448A1/en not_active Abandoned
- 2019-08-20 US US17/269,830 patent/US12221447B2/en active Active
- 2019-08-20 CN CN201980054524.XA patent/CN112654353A/zh active Pending
- 2019-08-20 BR BR112021003189-8A patent/BR112021003189A2/pt not_active Application Discontinuation
- 2019-08-20 SG SG11202101522WA patent/SG11202101522WA/en unknown
- 2019-08-20 JP JP2021509910A patent/JP2021534202A/ja active Pending
- 2019-08-20 TW TW108129703A patent/TW202021968A/zh unknown
- 2019-08-20 EP EP19852526.3A patent/EP3840745A4/en active Pending
- 2019-08-20 WO PCT/US2019/047309 patent/WO2020041344A1/en not_active Ceased
-
2021
- 2021-02-18 IL IL280952A patent/IL280952A/en unknown
- 2021-03-19 CO CONC2021/0003607A patent/CO2021003607A2/es unknown
-
2024
- 2024-12-09 US US18/973,967 patent/US20250122209A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534202A5 (enExample) | ||
| JP2013540776A5 (enExample) | ||
| JP2021527126A5 (enExample) | ||
| JP2010510237A5 (enExample) | ||
| RU2013119869A (ru) | Аналоги циклоспорина | |
| JP2018518537A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| IL286427B2 (en) | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease | |
| JP2015532295A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2018504393A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2017533922A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2017531673A5 (enExample) | ||
| EA201000848A1 (ru) | Ингибиторы протеинкиназы и их применение | |
| JP2017531689A5 (enExample) | ||
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| JP2015535247A5 (enExample) | ||
| JP2021535112A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| JP2024508903A5 (enExample) | ||
| AU2017261303A1 (en) | Ophthalmic compositions |